Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals is a biopharmaceutical royalty company that acquires, finances, and licenses rights to high-value medicines rather than developing drugs itself. It generates revenue mainly from royalties on partner product sales, plus Captisol material sales and license, milestone, and other contract income.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaEconomic rights to sales of partnered biopharmaceutical products, including commercial and late-stage programs.
Infrastructure-light cyclodextrin technology used to improve drug solubility and stability, generating material sales and royalties.
License fees, development, regulatory, and sales-based milestone payments from partner programs.
Asiakkaat
Ligand's customers are primarily biopharmaceutical companies that need capital, technology, or royalty monetization to advance drug programs. It also earns cash flows from commercial partners selling approved products, with Ligand taking a contractual share of sales or milestone-linked payments. The company is built to serve partners that want non-dilutive funding and access to platform technologies without adding heavy internal infrastructure.
Mid- to late-stage drug developers that receive financing or technology support in exchange for royalties or economic rights.
Companies marketing approved products that generate royalty revenue for Ligand based on partner sales.
Partners using Captisol or NITRICIL to improve formulation, solubility, or dosing of medicines.
Counterparties that sell royalty interests or embedded royalty rights to Ligand for upfront capital.
Strategia
Ligand is focused on disciplined capital deployment into differentiated royalty streams and on expanding its portfolio of late-stage and commercial biopharma assets. It is also using infrastructure-light platform technologies, especially Captisol and NITRICIL, to create incremental royalty opportunities while keeping corporate overhead lean. Recent portfolio actions, including spin-offs and the Pelthos transaction, show a strategy of simplifying the business and concentrating on high-margin royalty generation.
More assets reduce concentration risk and increase recurring cash flow sources.
Captisol and NITRICIL can generate royalties without heavy infrastructure investment.
Low overhead supports high margins and makes royalty cash flows more valuable.
Maantiede
Ligand is headquartered in the United States and its revenue is generated primarily through global partner product sales rather than direct manufacturing or distribution. Its royalty base is tied to medicines sold across major pharmaceutical markets, so performance depends on partner commercialization in the U.S. and internationally. The company has limited physical infrastructure, but its exposure is global through partner programs and regulatory regimes in the U.S., Europe, and other markets.
Riskit
Ligand's cash flows depend on partner product sales, partner execution, and the durability of royalty assets, so revenue can move with commercial performance and development outcomes. The business also has concentration and third-party risks, including reliance on a sole Captisol supplier, partner insolvency, and exposure to strategic transactions such as Pelthos. As a biopharma royalty model, it also faces regulatory, IP, and reimbursement risks that can affect product adoption and royalty collections.
- Dependence on partner product salesVaikutus: KorkeaTodennäköisyys: Kohtalainen
Royalty revenue is tied to commercial performance of third-party medicines, not Ligand-controlled operations.
Kohdistuu - Captisol sole-supplier concentrationVaikutus: KorkeaTodennäköisyys: Kohtalainen
A supply interruption could disrupt material sales and related revenue streams.
Kohdistuu: Captisol platform technology
- Partner development and regulatory failureVaikutus: KorkeaTodennäköisyys: Kohtalainen
Late-stage programs can fail or be delayed, reducing milestone and royalty potential.
Kohdistuu: Development-stage financing and licensed programs
- Partner insolvency or strategic shiftVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Counterparties may deprioritize programs or be unable to fund commercialization.
Kohdistuu: Collaboration partners and royalty counterparties
- Pelthos investment exposureVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Ligand retains equity and preferred stock exposure to a recently carved-out business.
Kohdistuu: Pelthos Therapeutics ownership and related investments
Kirjanpito
Harkinnanvaraiset erätIncome is recognized based on expected cash flows, which can change as partner products mature or underperform.
Vaikutus: Affects royalty revenue timing and volatility
Programs without reliable sales patterns are not accrued like mature royalties.
Vaikutus: Can delay revenue recognition until cash flows become more predictable
Regulatory, sales-based, and technology access payments are event-driven and uneven.
Vaikutus: Creates quarter-to-quarter revenue lumpiness
Royalty and technology assets may need write-downs if expected cash flows weaken.
Vaikutus: Can materially affect operating income
Embedded derivative instruments tied to partner programs can revalue each period.
Vaikutus: Can add non-cash volatility to earnings
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
LadRx Corp
Biological Products, (No Diagnostic Substances)
LadRx Corp is a Delaware-based biopharmaceutical research company focused on oncology drug discovery and clinical development.
Pelthos Therapeutics Inc.
PTHS · Biological Products, (No Diagnostic Substances)
Royalty Pharma plc
RPRX · Pharmaceutical Preparations
Royalty Pharma plc is a U.S.-listed biopharmaceutical royalty company organized through a holding-company structure in England and Wales.
Cadrenal Therapeutics, Inc.
CVKD · Pharmaceutical Preparations
Vincerx Pharma, Inc.
Pharmaceutical Preparations
Syndax Pharmaceuticals Inc
SNDX · Pharmaceutical Preparations
Syndax Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing and commercializing therapies for hematologic malignancies and other serious diseases.
Päivitetty: 24.9.2026